S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
ASX:MDC

Medlab Clinical Limited (MDC.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.22
MA: A$0.21
A$0.22
52-Week Range N/A
Volume36,677 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medlab Clinical Limited, a medical research and development facility, engages in the nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management. It also provides nutraceuticals for anti-inflammatory, cardiovascular support, endocrine support, gastrointestinal support, immunological support, infants and toddlers, metabolic support, musculoskeletal support, neurological support, sports performance, urogenital support, and weight management, as well as for men, pregnancy, seniors, teenagers, and women support. Medlab Clinical Limited was founded in 2012 and is headquartered in Botany, Australia.

MarketRank

Overall MarketRank

0.66 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 8188 0311
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.85 million
Book ValueA$0.04 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Receive MDC News and Ratings via Email

Sign-up to receive the latest news and ratings for MDC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medlab Clinical Limited (MDC.AX) (ASX:MDC) Frequently Asked Questions

What stocks does MarketBeat like better than Medlab Clinical Limited (MDC.AX)?

Wall Street analysts have given Medlab Clinical Limited (MDC.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medlab Clinical Limited (MDC.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Medlab Clinical Limited (MDC.AX)'s key competitors?

What other stocks do shareholders of Medlab Clinical Limited (MDC.AX) own?

Who are Medlab Clinical Limited (MDC.AX)'s key executives?

Medlab Clinical Limited (MDC.AX)'s management team includes the following people:
  • Dr. Sean Michael Hall, CEO & Director
  • Mr. Alan Dworkin, CFO, Company Sec. & COO
  • Mr. Ian Curtinsmith, Chief Information Officer
  • Dr. Luis Vitetta BSc(Hons), Grad Dip, Ph.D., Grad Dip Nutr, Director of Medical Research
  • Dr. David A. Rutolo, Director of Science

What is Medlab Clinical Limited (MDC.AX)'s stock symbol?

Medlab Clinical Limited (MDC.AX) trades on the ASX under the ticker symbol "MDC."

How big of a company is Medlab Clinical Limited (MDC.AX)?

Medlab Clinical Limited (MDC.AX) has a market capitalization of $0.00 and generates $2.85 million in revenue each year.

What is Medlab Clinical Limited (MDC.AX)'s official website?

The official website for Medlab Clinical Limited (MDC.AX) is www.medlab.co.

How can I contact Medlab Clinical Limited (MDC.AX)?

The company can be reached via phone at 61 2 8188 0311.

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.